<li>apremilast<p>oxcarbazepine will decrease the level or effect of apremilast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with strong CYP inducers results in a significant decrease of systemic exposure of apremilast, which may result in loss of efficacy</p></li><li>astemizole<p>oxcarbazepine will decrease the level or effect of astemizole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>axitinib<p>oxcarbazepine decreases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Selection of concomitant medication with no or minimal CYP3A4 induction potential is recommended.</p></li><li>bedaquiline<p>oxcarbazepine will decrease the level or effect of bedaquiline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of bedaquiline with strong CYP3A4 inducers due to potential for decreased therapeutic effect</p></li><li>bosutinib<p>oxcarbazepine decreases levels of bosutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers decreased bosutinib plasma concentration by ~85%.</p></li><li>cabozantinib<p>oxcarbazepine will decrease the level or effect of cabozantinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of cabozantinib with strong CYP3A4 inducers. If a strong CYP3A4 inducer is required, increase cabozantinib dose by 40 mg/day (Cometriq) or by 20 mg/day (Cabometyx). Resume previous dose 2-3 days after strong CYP3A4 inducer discontinued.</p></li><li>ceritinib<p>oxcarbazepine decreases levels of ceritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>cisapride<p>oxcarbazepine will decrease the level or effect of cisapride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>clopidogrel<p>oxcarbazepine decreases effects of clopidogrel by affecting hepatic enzyme CYP2C19 metabolism. Avoid or Use Alternate Drug. Clopidogrel efficacy may be reduced by drugs that inhibit CYP2C19. Inhibition of platelet aggregation by clopidogrel is entirely due to an active metabolite. Clopidogrel is metabolized to this active metabolite in part by CYP2C19.  .</p></li><li>cobicistat<p>oxcarbazepine will decrease the level or effect of cobicistat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration is necessary, monitor for lack or loss of virologic response from cobicistat</p></li><li>dabrafenib<p>oxcarbazepine decreases levels of dabrafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>deflazacort<p>oxcarbazepine will decrease the level or effect of deflazacort by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of deflazacort with moderate or strong CYP3A4 inducers.</p></li><li>dihydroergotamine<p>oxcarbazepine will decrease the level or effect of dihydroergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>dihydroergotamine intranasal<p>oxcarbazepine will decrease the level or effect of dihydroergotamine intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>dolutegravir<p>oxcarbazepine will decrease the level or effect of dolutegravir by  increasing metabolism. Avoid or Use Alternate Drug. Avoid coadministration; insufficient data to recommend dosage adjustment</p></li><li>dronedarone<p>oxcarbazepine will decrease the level or effect of dronedarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>eliglustat<p>oxcarbazepine will decrease the level or effect of eliglustat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A inducers significantly decreases eliglustat exposure; coadministration not recommended</p></li><li>elvitegravir<p>oxcarbazepine will decrease the level or effect of elvitegravir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid; coadministration with CYP3A inducers may result in decreased plasma concentrations of elvitegravir and/or a concomitantly administered protease inhibitor and lead to loss of therapeutic effect and to possible resistance</p></li><li>ergotamine<p>oxcarbazepine will decrease the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>erythromycin base<p>oxcarbazepine will decrease the level or effect of erythromycin base by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>erythromycin ethylsuccinate<p>oxcarbazepine will decrease the level or effect of erythromycin ethylsuccinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>erythromycin lactobionate<p>oxcarbazepine will decrease the level or effect of erythromycin lactobionate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>erythromycin stearate<p>oxcarbazepine will decrease the level or effect of erythromycin stearate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>ethinylestradiol<p>oxcarbazepine will decrease the level or effect of ethinylestradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. The efficacy of hormonal contraceptives may be reduced. Use of a nonhormonal contraceptive is recommended.</p></li><li>everolimus<p>oxcarbazepine will decrease the level or effect of everolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>hydrocodone<p>oxcarbazepine will decrease the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Caution when discontinuing CYP3A4 inducers that are coadministered with hydrocodone; plasma concentrations of hydrocodone may increase and can result in potentially fatal respiratory depression</p></li><li>ibrutinib<p>oxcarbazepine decreases levels of ibrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.  Strong CYP3A inducers decrease ibrutinib plasma concentrations by ~10-fold.</p></li><li>idelalisib<p>oxcarbazepine will decrease the level or effect of idelalisib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration; strong CYP3A4 inducers significantly decrease idelalisib systemic exposure</p></li><li>irinotecan<p>oxcarbazepine will decrease the level or effect of irinotecan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>irinotecan liposomal<p>oxcarbazepine will decrease the level or effect of irinotecan liposomal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>ivabradine<p>oxcarbazepine will decrease the level or effect of ivabradine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of ivabradine with moderate CYP3A4 inducers.</p></li><li>ivacaftor<p>oxcarbazepine decreases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with strong CYP3A4 inducers; systemic exposure of ivacaftor substantially reduced (ie, ~9-fold).</p></li><li>ixazomib<p>oxcarbazepine will decrease the level or effect of ixazomib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of ixazomib with strong CYP3A inducers. Strong inducers have been shown to decrease ixazomib Cmax by 54% and AUC by 74%.</p></li><li>lovastatin<p>oxcarbazepine will decrease the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>macitentan<p>oxcarbazepine will decrease the level or effect of macitentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministering macitentan with strong CYP3A4 inducers </p></li><li>netupitant/palonosetron<p>oxcarbazepine will decrease the level or effect of netupitant/palonosetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Netupitant is mainly metabolized by CYP3A4; avoid use in patients who are chronically using a strong CYP3A4 inducer</p></li><li>olaparib<p>oxcarbazepine will decrease the level or effect of olaparib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with strong CYP3A4 inducers</p></li><li>osimertinib<p>oxcarbazepine will decrease the level or effect of osimertinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of osimertinib with strong CYP3A inducers.</p></li><li>palbociclib<p>oxcarbazepine will decrease the level or effect of palbociclib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A inducers decrease palbociclib plasma exposure by ~85%.</p></li><li>pomalidomide<p>oxcarbazepine decreases levels of pomalidomide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>ponatinib<p>oxcarbazepine decreases levels of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid unless the coadministration outweighs the possible risk of ponatinib underexposure; monitor for signs of reduced efficacy.</p></li><li>ranolazine<p>oxcarbazepine will decrease the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>ribociclib<p>oxcarbazepine will decrease the level or effect of ribociclib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of ribociclib with strong CYP3A inducers should be avoided.</p></li><li>rolapitant<p>oxcarbazepine will decrease the level or effect of rolapitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Long-term coadministration of strong CYP3A4 inducers with rolapitant may significantly decrease rolapitant efficacy.</p></li><li>romidepsin<p>oxcarbazepine will decrease the level or effect of romidepsin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>sertindole<p>oxcarbazepine will decrease the level or effect of sertindole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>sildenafil<p>oxcarbazepine will decrease the level or effect of sildenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Potent CYP3A4 inducers are expected to cause substantial decreases in sildenafil plasma levels</p></li><li>silodosin<p>oxcarbazepine will decrease the level or effect of silodosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>simeprevir<p>oxcarbazepine decreases levels of simeprevir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inducers may significantly decrease simeprevir plasma concentrations and result in loss of therapeutic effect.</p></li><li>simvastatin<p>oxcarbazepine will decrease the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>sirolimus<p>oxcarbazepine will decrease the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>sofosbuvir<p>oxcarbazepine will decrease the level or effect of sofosbuvir by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. P-gp inducers decrease sofosbuvir levels, and therefore decrease conversion to sofosbuvir's active metabolite (GS-331007) responsible for 90% of pharmacologic effect</p></li><li>sofosbuvir/velpatasvir<p>oxcarbazepine will decrease the level or effect of sofosbuvir/velpatasvir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Velpatasvir is a substrate of CYP2B6, CYP2C8, and CYP3A4. Drugs that are moderate-to-potent inducers of CYP2B6, CYP2C8, or CYP3A4 may significantly decrease velpatasvir plasma concentrations, leading to potentially reduced therapeutic effect.</p></li><li>sonidegib<p>oxcarbazepine will decrease the level or effect of sonidegib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sonidegib with strong or moderate CYP3A4 inducers.</p></li><li>telaprevir<p>oxcarbazepine decreases levels of telaprevir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of telaprevir with CYP3A inducers may significantly reduce telaprevir plasma concentrations resulting in reduced efficacy .</p></li><li>terfenadine<p>oxcarbazepine will decrease the level or effect of terfenadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>tolvaptan<p>oxcarbazepine will decrease the level or effect of tolvaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>trabectedin<p>oxcarbazepine will decrease the level or effect of trabectedin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>ulipristal<p>oxcarbazepine will decrease the level or effect of ulipristal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>vemurafenib<p>oxcarbazepine decreases levels of vemurafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>venetoclax<p>oxcarbazepine will decrease the level or effect of venetoclax by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of venetoclax with strong or moderate CYP3A inducers. Consider alternative treatment with agents that have less CYP3A induction.</p></li><li>vorapaxar<p>oxcarbazepine decreases levels of vorapaxar by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li>